Rapid Dose Announces Proposed Issuance of Shares as Payment of Director Fees
Burlington, Ontario--(Newsfile Corp. - December 24, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces that it has agreed with its non-management directors (the "Directors") to issue common shares (the "Debt Shares") to such Directors in exchange for the cancellation of director fees owing. Each of the five Directors is owed $10,000 in director fees for each of the fiscal quarters ended May 31, August 31 and November 30, 2024, for an aggregate amount of...
2024-12-24 8:49 AM EST
Rapid Dose Announces Proposed Equity Private Placement Financing and Proposed Shares for Debt Settlement
Burlington, Ontario--(Newsfile Corp. - December 10, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that it plans to complete an equity private placement financing (the "Financing") for up to $6,000,000 of gross proceeds, consisting of up to 24,000,000 units (the "Units") at a price of $0.25 per Unit. Each Unit will consist of one (1) Common Share and one (1) Common Share Purchase Warrant (a "Warrant"). Each Warrant will be exercisable for one (1)...
2024-12-10 4:15 PM EST
Rapid Dose Therapeutics Corp. Files Patent Application for Lidocaine Oral Thin Strip
Burlington, Ontario--(Newsfile Corp. - December 5, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotechnology company, is pleased to announce that it has filed a patent application for its Lidocaine Oral Thin Film Strip, with the Canadian Intellectual Property Office ("CIPO").Dentists commonly perform dental procedures using anesthesia administered through injection by needle, which is commonly preceded by a spray, gel, jelly, cream, or ointment. RDT...
2024-12-05 5:24 PM EST
Rapid Dose Announces Closing of Final Tranche of Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - October 30, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a second and final tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of $542,000.The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.The Financing allowed for a...
2024-10-30 5:05 PM EDT
Rapid Dose Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - October 1, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on September 30, 2024 under the terms of the Financing and the Notes, and expects to issue the Common...
2024-10-01 6:19 PM EDT
Rapid Dose Provides Update on Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - September 16, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated August 7, 2024, regarding a proposed equity private placement financing (the "Financing"), the Company has received an extension from the Canadian Securities Exchange allowing it to close the Financing on or before October 29, 2024. This previously announced Financing contemplates an aggregate of up to...
2024-09-16 7:38 PM EDT
Rapid Dose Announces Closing of First Tranche of Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - July 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") is pleased to announce that it has closed a first tranche of its previously announced equity private placement financing (the "Financing") for aggregate gross proceeds of $309,000.The proceeds of the Financing will be used for research and development, capital expansion, repayment of debt and general working capital requirements.The Financing allowed for a maximum of...
2024-07-22 7:15 AM EDT
Rapid Dose Therapeutics Announces Payment in Shares for Interest on Secured Debt
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on June 30, 2024 under the terms of the Financing and the Notes, and expects to issue the Common Shares no...
2024-07-02 7:25 PM EDT
Rapid Dose Therapeutics Reports Fiscal Year 2024 Financial Results
Burlington, Ontario--(Newsfile Corp. - July 2, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), is pleased to announce the filing of its financial results for the year ended February 29, 2024. Mark Upsdell, Chairman and Chief Executive Officer, stated, "Over the past several years, our product roadmap has expanded from our Nutraceutical business to complementary markets such as Pharmaceutical, Dental, Nicotine, Cannabis and Vaccine products. These innovative...
2024-07-02 7:15 AM EDT
Rapid Dose Therapeutics Vaccine Delivery Study Receives Mitacs Accelerate Grant
Burlington, Ontario--(Newsfile Corp. - June 25, 2024) - Rapid Dose Therapeutics Corp. ("RDT" or the "Company") trading on the Canadian Securities Exchange ("CSE") under the symbol DOSE is pleased to announce the recent award of a Mitacs Accelerate grant, with a value of $30,000 in May 2024 in addition to $55,000 in 2023, to continue the development of Thin Polymer Films for Vaccine Delivery Project, led by Prof. Alex Adronov, of McMaster University. This grant-funded research project aims to...
2024-06-25 7:15 AM EDT
Rapid Dose Provides Update on Common Share Private Placement
Burlington, Ontario--(Newsfile Corp. - June 19, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") today announced that further to its press release dated May 8, 2024, regarding a proposed equity private placement financing (the "Financing"), the Company has received an extension from the Canadian Securities Exchange allowing it to close the Financing on or before August 8, 2024.This previously announced Financing contemplates an aggregate of up to $6,000,000 of gross...
2024-06-19 7:54 AM EDT
Rapid Dose Therapeutics Commits to NFL-Funded Clinical Trial Application
Burlington, Ontario--(Newsfile Corp. - May 29, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announces its collaboration in the National Football League (NFL) – funded clinical trial program entitled "Naturally Produced Cannabinoids for Pain Management and Neuroprotection from Concussion and Participation in Contact Sports" led by Dr. J. Patrick Neary and researchers at the University of Regina. RDT will partake in a randomized, two-arm clinical study, which is...
2024-05-29 10:40 AM EDT
Rapid Dose Therapeutics and McMaster University's Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films for Rapid Drug Delivery
Burlington, Ontario--(Newsfile Corp. - May 22, 2024) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") trading on the Canadian Securities Exchange ("CSE") under the symbol DOSE in partnership with McMaster University ("McMaster") is pleased to announce the publication of the results of their collaborative research project titled "Incorporation of Loratadine-Cyclodextrin Complexes in Oral Thin Films ("OTF") for Rapid Drug Delivery" in the Journal of Pharmaceutical...
2024-05-22 8:00 AM EDT
Rapid Dose Therapeutics and Thrive Cannabis Sign MOU to Provide Quickstrip(TM) Oral Thin Strips Under a White Label Manufacturing Agreement
Burlington, Ontario--(Newsfile Corp. - March 13, 2019) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian bio-technology company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has signed a Memorandum of Understanding ("MOU") February 27, 2019 with THRIVE Cannabis ("THRIVE") providing THRIVE the rights to sell oral thin film strips with RDT's proprietary QuickStrip™ technology using cannabis distillates provided by...
2019-03-13 8:31 AM EDT
Rapid Dose Therapeutics Corp. Grants Stock Options
Burlington, Ontario--(Newsfile Corp. - March 11, 2019) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Corporation") announces the grant of options to directors, officers, eployess and consultants to purchase 4,526,000 common shares of the Corporation, exercisable at $0.82 per share at any time on or before March 11, 2024. The grants are subject to the terms of RDT's stock option plan. In accordance with securities regulatory requirements, any shares issued pursuant to the exercise...
2019-03-11 8:31 AM EDT
Rapid Dose Therapeutics Wins Summary Judgment Against CTT Pharmaceuticals. CTT's Case Is Dismissed
Burlington, Ontario--(Newsfile Corp. - March 5, 2019) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian bio-technology company focused on innovative drug and active ingredient delivery solutions, is pleased to announce it has been successful in obtaining a summary judgment against CTT Pharmaceutical Holdings, Inc. ("CTT") dismissing CTT's lawsuit against RDT. Justice E.M. Morgan of the Ontario Superior Court of Justice wrote in the Court's decision, "There is no...
2019-03-05 5:38 PM EST
Rapid Dose Therapeutics Corp. Announces Amalgamation with Its Wholly-Owned Subsidiary, Rapid Dose Therapeutics Inc.
Burlington, Ontario--(Newsfile Corp. - March 1, 2019) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Corporation") is pleased to announce the completion of a vertical amalgamation (the "Amalgamation") with its wholly-owned subsidiary, Rapid Dose Therapeutics Inc., pursuant to section 177 of the Business Corporations Act (Ontario). The Amalgamation did not require shareholder approval and was completed to simplify the corporate structure of RDT. No securities were issued in...
2019-03-01 4:50 PM EST
Rapid Dose Therapeutics Business Update
Burlington, Ontario--(Newsfile Corp. - February 26, 2019) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian bio-technology company focused on innovative drug delivery solutions, is pleased to provide a business update. RDT's proprietary QuickStrip™ technology is a Quick, Convenient, Precise, Discreet™ oral fast-dissolving drug delivery system for both nutraceutical and cannabis products.RDT continues its efforts to develop its business, including expanding the...
2019-02-26 8:40 AM EST
Rapid Dose Therapeutics Enters Into Advisory Agreement with Spinnaker Capital Markets
Burlington, Ontario--(Newsfile Corp. - February 14, 2019) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT") is pleased to announce that it has appointed Spinnaker Capital Markets Inc. ("Spinnaker") as its capital markets and investor relations advisor. Spinnaker is a Toronto-based advisory firm which provides public companies with an array of services tailored to raise capital, target and attract institutional and retail investors, increase shareholder value and focus on developing and...
2019-02-14 8:13 AM EST
Rapid Dose Therapeutics Announces Appointment of Dr. Gabriela Radulescu as Medical Director
Burlington, Ontario--(Newsfile Corp. - January 23, 2019) - Rapid Dose Therapeutics (CSE: DOSE) ("RDT") is pleased to announce the appointment of Dr. Gabriela Radulescu as Medical Director for RDT.Dr. Radulescu is a physician with 20 years of experience in the pharmaceutical industry. She brings to the RDT team strong strategic and operational medical leadership that will enhance the dialogue with pharmaceutical companies wanting to offer QuickStrip™ technology to their patient base. Dr....
2019-01-23 7:00 AM EST